Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
-
21
-
22
-
23
-
24
-
25
-
26
TUDCA decreases ER stress in HOX neonatal rat lungs.
Published 2022“…(<b>C</b>) In IHC stain, P-IRE1α levels are decreased (40.8±3.5 A.U. <i>vs</i> 53.1±5.0 A.U., p<0.001, n = 6, 3 for each sex) in chronic hyperoxia exposed neonatal rat lungs by TUDCA. …”
-
27
Shiga toxin expression in O157 following treatment with hGRNL, bNK2A, and pNKL peptides.
Published 2023Subjects: -
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF
Published 2023“…Background<p>We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021.</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …”
-
37
-
38
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
39
-
40